Assenagon Asset Management S.A. Sells 25,443 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Assenagon Asset Management S.A. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 207,788 shares of the biopharmaceutical company’s stock after selling 25,443 shares during the period. Assenagon Asset Management S.A.’s holdings in Regeneron Pharmaceuticals were worth $160,545,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. WPG Advisers LLC boosted its stake in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the period. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $29,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $800.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Stock Up 1.0%

REGN stock opened at $623.93 on Thursday. The company has a market cap of $65.96 billion, a PE ratio of 15.20, a price-to-earnings-growth ratio of 1.36 and a beta of 0.25. The business has a 50-day simple moving average of $668.64 and a 200 day simple moving average of $729.81. Regeneron Pharmaceuticals, Inc. has a 52 week low of $514.79 and a 52 week high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.22 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.